Investors in PROCEPT BioRobotics have chance to lead fraud lawsuit

NEW YORK, Sept. 5, 2026 /CourierPR/ -- Investors who purchased common stock of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) between February 28, 2024, and February 25, 2026, inclusive, have an opportunity to lead a securities fraud lawsuit, according to a notice from Rosen Law Firm, a global investor rights law firm.

Rosen Law Firm is reminding investors of the upcoming September 22, 2026, deadline for selecting a lead plaintiff in the class action lawsuit. The firm advises investors who may be entitled to compensation to contact them for information on how to join the case.

"The Class Period saw significant misrepresentations and omissions by the company regarding its financial performance and sales strategies," said Phillip Kim, Esq., a partner at Rosen Law Firm. "Investors who purchased PRCT stock during this period are encouraged to act quickly to ensure their rights are protected."

According to the lawsuit, during the Class Period, PROCEPT BioRobotics used an extensive discount program to incentivize bulk orders, leading to artificially inflated sales and revenues. The lawsuit claims that these orders were unsustainable and significantly exceeded actual procedure demand. This, in turn, resulted in a surplus of field inventory and overstocking among customers, with more than 10,000 excess units by the end of the Class Period.

"The company's financial statements and public statements were misleading, failing to disclose the true extent of the discount program and its impact on sales," said Kim. "This has led to an overreliance on short-term sales boosts, which may not be sustainable in the long run."

Rosen Law Firm, known for its track record in securities class action lawsuits, is representing investors in this case. The firm has secured significant settlements in the past, including a $438 million recovery in 2019 and the largest settlement ever against a Chinese company. Rosen Law Firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has been ranked in the top four every year since 2013.

"Many law firms issue notices but lack the experience and resources to effectively represent investors," said Kim. "It's crucial for investors to select a firm with a proven track record of success."

The lawsuit alleges that PROCEPT BioRobotics' financial statements were materially false and misleading, and that the company failed to disclose the true impact of its discount program on sales and inventory levels. As a result, the company's guidance for 2025 handpiece sales and revenue was not based on a reasonable factual basis, leading to significant operational and financial risks.

"The true details of the company's practices entered the market, and investors suffered significant losses as a result," said Kim.

Until a class is certified, investors are not represented by counsel unless they retain one. Investors may also choose to remain absent class members and do nothing at this point.

For updates, follow Rosen Law Firm on LinkedIn, Twitter, or Facebook.